Welcome to our dedicated page for EVTCY news (Ticker: EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.
Evotec SE (EVTCY), a global leader in drug discovery and development, provides this dedicated news hub for tracking its latest corporate developments and scientific advancements. This page serves as the definitive source for press releases, financial updates, and strategic partnership announcements from the biotechnology innovator.
Investors and industry professionals will find curated updates on Evotec's R&D milestones, regulatory progress, and collaborative ventures with pharmaceutical leaders. Our aggregation includes earnings reports, acquisition activity, and innovations in precision medicine – all critical for assessing the company's position in competitive life sciences markets.
Key updates cover therapeutic developments in neurology, oncology, and infectious diseases, alongside operational expansions and technology platform enhancements. Bookmark this resource to monitor how Evotec's integrated research model translates scientific breakthroughs into sustainable growth across global markets.
Evotec has received a milestone payment of €3 million from Bayer AG due to the advancement of BAY 2395840 into Phase II clinical trials for diabetic neuropathic pain (DNP). This investigational oral antagonist targets the bradykinin receptor B1, known to influence pain perception. The Phase II trial aims to assess its safety and efficacy compared to a placebo and is expected to conclude by the end of 2022. Dr. Cord Dohrmann expressed optimism about BAY 2395840's potential to offer a new therapeutic option for DNP patients.
Evotec has launched E.MPD, a global molecular patient database, aimed at enhancing drug development through AI and machine learning technologies. The initiative is part of Evotec's strategy to increase the probability of success (PoS) in therapeutics research. The company confirmed its goals for Action Plan 2025 and announced the appointment of Dr. Matthias Evers as Chief Business Officer to lead business development. Evotec is focused on establishing itself as a leader in precision medicine, leveraging partnerships and innovative technologies.
Evotec announced a collaboration with the University of Bristol to enhance its molecular patient database focusing on nephrotic syndrome. This partnership grants Evotec access to an international cohort's longitudinal clinical data and biospecimens from hundreds of patients across Asia, India, and Africa. Evotec plans to utilize its multi-omics platforms, EVO panOmics and EVO panHunter, to identify disease mechanisms and diagnostic markers, aiming for new targeted therapies. This collaboration could significantly impact treatment options for nephrotic syndrome patients.
Evotec SE announced that Bayer has discontinued the development of eliapixant (BAY1817080), an investigational P2X3 receptor antagonist. Bayer determined that the risks outweigh the benefits after reviewing the available data. As a result, Evotec regains rights to all P2X3 assets and will evaluate the data and options moving forward. The company states that this change does not affect its strategic goals outlined in the Action Plan 2025.
Evotec SE announced a partnership with Boehringer Ingelheim focusing on induced pluripotent stem cell (iPSC)-based disease modeling for ophthalmologic disorders. This collaboration aims to identify and validate therapeutic targets through phenotypic screening and Evotec's PanOmics platform, addressing a significant unmet need in vision-related diseases. The partnership includes undisclosed upfront payments and ongoing royalties for successful therapeutic development. Dr. Cord Dohrmann highlighted the potential of their unique methodologies to deliver effective drugs.
Evotec SE has announced a drug discovery collaboration with Eli Lilly focusing on metabolic diseases, particularly kidney diseases and diabetes. This partnership will leverage Evotec's extensive kidney disease patient database and metabolic expertise to identify novel therapeutic targets. Over three years, Lilly can select up to five programs, potentially generating up to $1 billion in total value for Evotec, including milestone payments and royalties. This collaboration underscores Evotec's commitment to innovative drug development in underserved therapeutic areas.
Evotec expands its collaboration with Bristol Myers Squibb to address neurodegenerative diseases through a novel targeted protein degradation strategy. This initiative includes payments totaling US$ 15 million from Bristol Myers Squibb, enhancing their access to Evotec's proprietary platform. The collaboration, initiated in December 2016, aims to develop treatments for diseases like Alzheimer's, focusing on disease-causing proteins. Evotec's advanced iPSC platform, one of the largest in the industry, is utilized for innovative drug discovery and development.
Evotec SE has secured an US$ 18 million grant from the Bill & Melinda Gates Foundation to support an integrated drug discovery program aimed at women's health and contraceptive technology. This initiative will utilize Evotec's advanced R&D platforms and AI/ML molecular design tools to develop first-in-class drug candidates. The grant will help in efficiently transitioning concepts to pre-clinical development.
Dr. Craig Johnstone, COO of Evotec, expressed excitement about the project's potential to create impactful solutions for women's health.
Evotec SE has received an $18 million grant from the Bill & Melinda Gates Foundation to support a fully integrated drug discovery program targeting women's health and contraceptive technology. The project will utilize Evotec's advanced drug discovery platforms and AI/ML tools to develop a first-in-class program, taking it from concept to pre-clinical development. Dr. Craig Johnstone, COO of Evotec, expressed excitement about the potential impact of the project on women's health and the trust placed in their capabilities by the Gates Foundation.
Evotec and EQRx announced a strategic partnership to utilize Evotec's data-driven drug discovery platform aimed at developing affordable medicines. This collaboration will expedite EQRx's pipeline in oncology and immunology, with Evotec leading the drug discovery and pre-clinical efforts, while EQRx handles clinical development and commercialization. The partnership also includes a variable profit share for Evotec from successful asset development. This alliance aligns with EQRx's commitment to provide innovative therapies at lower costs.
